Statement of Need
Despite important advances in the treatment of non-small cell lung cancer (NSCLC) over the last several years, effective treatment of advanced-stage disease remains challenging.1 Although best practices have been outlined by the National Comprehensive Cancer Network2, clinicians are often unable to utilize the preferred agent or combination of agents due to advanced disease stage, advanced patient age, poor performance status, or a potential increased risk of drug-related toxicity.2 The development of screening strategies that allow for early diagnosis and comprehension of tumor biology will likely improve outcomes in these patients, as will utilization of investigational agents that are associated with positive patient response.2,3 Preliminary results appear promising, and researchers are hopeful that large strides will be made towards extended life in NSCLC patients over the next few years.
1. American Cancer Society. Cancer Facts and Figures 2012. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed June 9, 2012.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Version 3.2012. Available at: www.nccn.org/professionals/physician_gls/PDF/nscl.pdf. Accessed June 9, 2012.
3. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005 Sep 1;23(25):5900-5909.
This activity is designed for oncologists, radiation oncologists, thoracic surgeons, and registered nurses involved in the care of patients with lung cancer.
After taking part in this educational activity, participants should be better able to:
- Perform diagnostic/molecular testing (EGFR, KRAS, EML4-ALK) for NSCLC according to current evidence-based guidelines.
- Optimize individual therapy plans for patients based on diagnostic/molecular testing results.
- Incorporate data regarding novel therapeutic agents that can provide the most advanced treatment for patients when appropriate.
- For Registered Nurses: Provide appropriate care and counsel for patients and their families.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
The Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.30 contact hours is provided by Postgraduate Institute for Medicine.
Daniel Morgensztern, MD
Division of Oncology
Yale University School of Medicine
New Haven, Connecticutt
The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Daniel Morgensztern, MD, has no affiliations with commercial interests to disclose.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Emma Hitt, PhD, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, RMEI, LLC, and Genentech do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, RMEI, LLC, or Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly sponsored/co-provided by RMEI, LLC and Postgraduate Institute for Medicine
This activity is supported by an educational grant from Genentech.
Method of Participation
To complete this activity and receive a statement of credit, participants must:
1. Review all contents of this activity
2. Complete and submit the learning assessment and evaluation form
3. Score at least 70% on the learning assessment
There are no fees for participating and receiving CME credit for this activity. During the period August 29, 2012 through August 29, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity.
To obtain credit, a score of 70% or better is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
For questions regarding the content of this activity, contact the accredited provider for this continuing education activity: firstname.lastname@example.org or visit www.pimed.com. For technical assistance, contact email@example.com.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.